Rivaroxaban for Scheduled Work-up of DVT - The Ri-Schedule Study

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 625 participants.

Also called NCT02486445

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 625 participants (enrolled count) (from the registry)
Sponsor
Ostfold Hospital Trust (from the registry)
Registry
  • NCT NCT02486445
Other papers using this trial's data
  • Clinical use and safety of empiric anticoagulation during diagnostic work-up for deep vein thrombosis Hematology (Amsterdam, Netherlands), 2025-12 DOI, PubMed 41116683
  • Safety of a strategy combining D-dimer testing and whole-leg ultrasonography to rule out deep vein thrombosis Blood advances, 2020-10-27 DOI, PubMed 33057634, PMC7594381 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Norway (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02486445. Allocation not applicable; no masking; primary purpose treatment. Start 2015-03 (actual); primary completion 2018-11-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rivaroxaban for Scheduled Work-up of DVT - The Ri-Schedule Study
Acronym
Ri-Schedule
Condition
Deep Venous Thrombosis
Intervention (Drug)
Rivaroxaban
Lead sponsor
Ostfold Hospital Trust (class: other)

Record details

Record id
cardio:ct-nct02486445
Content hash
ae5f64dee18d86a33d9c852b3d0bcdf05c04bf54c3b5ee9b693b85bf7a57a90f